<DOC>
	<DOCNO>NCT00540579</DOCNO>
	<brief_summary>Because activity CC-4047 address numerous mechanism carcinoma growth inhibition - include , limited anti-angiogenesis - CC-4047 select development part induction chemotherapy regimens solid tumor . This study pancreatic cancer design determine appropriate CC-4047 dose regimen combination gemcitabine .</brief_summary>
	<brief_title>CC-4047 With Gemcitabine Untreated Advanced Carcinoma Pancreas</brief_title>
	<detailed_description>Phase I Primary : • To determine maximum tolerate dose ( MTD ) evaluate safety profile oral CC-4047 give day 1-21 combination gemcitabine day 1 , 8 , 15 every 28 day subject advance pancreatic carcinoma . Secondary : • To explore anti-tumor activity combination CC-4047 gemcitabine combination therapy subject advance pancreatic carcinoma . Phase II Primary : • To explore anti-tumor activity combination CC-4047 day 1-21 gemcitabine day 1 , 8 , 15 every 28 day subject advance pancreatic carcinoma . Secondary : • To evaluate safety profile combination CC-4047 gemcitabine combination therapy subject advance pancreatic carcinoma .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age ≥ 18 year time signing informed consent form . 3 . Must able adhere study visit schedule protocol requirement . 4 . Histological cytological documentation adenocarcinoma pancreas metastasis amenable curative surgery definitive radiation . Patients locally advanced disease eligible . 5 . Radiographic clinical evidence measurable advanced metastatic pancreatic carcinoma . Subjects must measurable disease accord international criterion propose Response Evaluation Criteria Solid Tumors ( RECIST ) Committee target lesion ( see Appendix 14.2 ) . 6 . Subjects may previously treat adjuvant radiation therapy 5fluorouracil Gemzar radiosensitizer adjuvant set currently evidence progression . Following completion XRT , adjuvant chemotherapy either Gemzar 5FU permit . No prior Gemzar® metastatic disease primary treatment locally advanced disease allow . Gemzar® use solely radiation sensitizer adjuvant setting permit . 7 . ECOG performance status 0 1 . 8 . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL 10 14 day prior within 24 hour start CC4047 must either commit continue abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take CC4047 . FCBP must also agree ongoing pregnancy test . Men must agree father child agree use condom partner child bear potential . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure ( see Appendix 14.6 ) . 1 . Pregnant lactating female . 2 . Any serious medical condition psychiatric illness prevents study subject signing informed consent form place study subject unacceptable risk participates study . 3 . Prior therapy CC4047 , lenalidomide , thalidomide . 4 . Prior use systemic therapy treatment adenocarcinoma pancreas exception 5fluorouracil Gemzar® radiosensitizer adjuvant set 5 . Concurrent use anticancer agent . 6 . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) Platelet count &lt; 100,000 cells/ mm3 ( 100 x 109/L ) Serum creatinine &gt; 2.5 mg/dL ( 221 μmol/L ) Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) ; case liver metastases &gt; 5 x ULN Serum total bilirubin &gt; 2.0 mg/dL ( 34 μmol/L ) 7 . Surgery radiation therapy within 14 day study enrollment outline . Surgery within 14 day start study ( patient must recover effect surgery ; 7 day may consider minor procedure ) . Palliative radiation therapy within 14 day start study . The radiation therapy may site measurable disease . Adjuvant therapy permit accordance inclusion criterion . 8 . Prior history malignancy ( except basal cell squamous cell carcinoma carcinoma situ cervix breast , localized prostate cancer PSA &lt; 1.0 mg/dL ) unless subject free disease ≥ 3 year . 9 . Known brain leptomeningeal disease ( CT scan MRI brain required case clinical suspicion central nervous system involvement ) . 10 . Grade ≥ 2 neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Untreated</keyword>
	<keyword>Advanced</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>CC-4047</keyword>
</DOC>